• Takeda, Ovid to co-develop TAK-935 for paediatric epilepsies firstwordpharma
    January 19, 2017
    Takeda and Ovid Therapeutics on Wednesday announced a global collaboration to jointly develop and commercialise the Japanese company's experimental selective CH24H inhibitor TAK-935 for the treatment of rare paediatric epilepsies.
PharmaSources Customer Service